Results 31 to 40 of about 94 (55)

Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. [PDF]

open access: yesPharmacol Res, 2018
Conklin LS   +31 more
europepmc   +1 more source

Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. [PDF]

open access: yesEur J Med Res, 2012
Gerber PA   +11 more
europepmc   +1 more source

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. [PDF]

open access: yesSteroids, 2018
Hoffman EP   +9 more
europepmc   +1 more source

Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. [PDF]

open access: yesLife Sci Alliance, 2019
Heier CR   +11 more
europepmc   +1 more source

VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. [PDF]

open access: yesCell Mol Neurobiol, 2015
Dillingham BC   +12 more
europepmc   +1 more source

Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). [PDF]

open access: yesSupport Care Cancer, 2012
Atherton PJ   +6 more
europepmc   +1 more source

Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy: Results From the Phase 2b Clinical Trial.

open access: yesJ Clin Endocrinol Metab
Ahmet A   +7 more
europepmc   +1 more source

Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo. [PDF]

open access: yesPLoS One, 2014
Zhang N   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy